MeMed’s Mission: Pressing Its Fingerprint Against AMR
Executive Summary
Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.
You may also be interested in...
Paragraf Is Finding A Way To Bring Graphene To Diagnostics
The UK-based company is creating a range of diagnostic sensors built using graphene, allowing for faster, more sensitive testing products.
Finding A Way To Bring Graphene To Diagnostics
UK-based Paragraf is working on a range of diagnostic sensors built using graphene, allowing for faster, more sensitive testing products.
MeMed Secures $93M Financing To Commercialize Diagnostics Platform
The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.